PROGRESSIVE SUPRANUCLEAR PALSY TREATMENT MARKET ANALYSIS

Progressive Supranuclear Palsy Treatment MarketSize and Trends

The global progressive supranuclear palsy treatment market is estimated to be valued at US$ 14.38 million in 2020 and is expected to exhibit a CAGR of 5.3% during the forecast period (2020-2027).

The increasing product development and ongoing trials is expected to propel growth of the global progressive supranuclear palsy treatment market

Market- Trends:

Major players in the market are focused on drug development for progressive supranuclear palsy treatment, which is expected to boost the market growth over the forecast period. For instance, in September 2020, Alzprotect announced the recruitment of the first five patients to be participated in its Phase IIa clinical trial with its drug candidate AZP2006 (EZEPROGIND) for progressive supranuclear palsy (PSP) treatment. PSP is an orphan disease and moreover, the company received an orphan drug designation by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).

Increasing incidence of progressive supranuclear palsy in North America is expected to boost the market growth

North America is expected to hold a dominant position in the global progressive supranuclear palsy treatment market, owing to increasing new cases of progressive supranuclear palsy in this region. For instance, according to the National Organization for Rare Disorders (NORD), an article published in 2017 reports that progressive supranuclear palsy (PSP affects around 20,000 people in the U.S. each year. The study also states that PSP may affect as many as 5 in 100,000 people and males are affected more often than females.